Nuvo Pharmaceuticals (TSX:NRI) appointed Jesse Ledger as CEO, succeeding John London who continues as executive chairman and a director.
Mr. Ledger was previously president of Nuvo and continues in that position. His appointment is the final step in a CEO succession plan adopted by the Nuvo board in 2016. Dan Chicoine, previously chairman of Nuvo, will continue as a member of the board.
Mr. Ledger has over 15 years of pharmaceutical experience with a proven expertise in business development. Prior to joining Nuvo in April 2015, he was VP of business development and international business at Tribute Pharmaceuticals Canada.
“Jesse has proven himself to be a strong energetic leader with business development acumen and contacts and the drive to make Nuvo a bigger, more diversified and more profitable pharmaceutical company,” Mr. London said in a statement.
“My goal is to make Nuvo a growth-oriented pharmaceutical company through the expansion and diversification of our proprietary-product portfolio and the continued global expansion of our Pennsaid 2% business,” Mr. Ledger said.
